Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

Breast cancer (advanced or metastatic) - lapatinib: second appeal information  

Breast cancer (advanced or metastatic) - lapatinib: second notice of appeal information  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision ^{PDF 56 KB} 14 October 2010  

Breast cancer (advanced or metastatic) - lapatinib: appeal announcement information  

Appeal received  

Appeal received ^{PDF 49 KB} 17 August 2010  

Initial scrutiny letter  

Initial scrutiny letter ^{PDF 34 KB} 17 August 2010  

Response to scrutiny letter  

Response to scrutiny letter ^{PDF 34 KB} 17 August 2010  

Final scrutiny letter  

Final scrutiny letter ^{PDF 20 KB} 17 August 2010  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination information  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination ^{PDF 234 KB} 10 June 2010  

Response to consultee, commentator and public comments on the appraisal consultation document (ACD 3)  

Response to consultee, commentator and public comments on the appraisal consultation document (ACD 3) ^{PDF 96 KB} 09 June 2010  

Consultee and commentator comments on the ACD  

GlaxoSmithKline  

GlaxoSmithKline ^{PDF 43 KB} 10 June 2010  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support ^{PDF 12 KB} 10 June 2010  

Royal College of Nursing  

Royal College of Nursing ^{PDF 11 KB} 09 June 2010  

The Royal College of Pathologists  

The Royal College of Pathologists ^{PDF 11 KB} 10 June 2010  

NCRI Breast Clinical Studies Group/RCP/RCR/ACP/JCCO  

NCRI Breast Clinical Studies Group/RCP/RCR/ACP/JCCO ^{PDF 54 KB} 10 June 2010  

Department of Health  

Department of Health ^{PDF 23 KB} 10 June 2010  

Welsh Assembly Government  

Welsh Assembly Government ^{PDF 18 KB} 10 June 2010  

Roche  

Roche ^{PDF 11 KB} 10 June 2010  

Letter to consultees and commentators  

Letter to consultees and commentators ^{PDF 15 KB} 10 June 2010  

Letter to Guidance Executive - prepared by Professor Philip Home (Vice-Chair of Committee)  

Letter to Guidance Executive - prepared by Professor Philip Home (Vice-Chair of Committee) ^{PDF 21 KB} 10 June 2010  

Breast cancer (advanced or metastatic) - lapatinib: (2nd line) paper - post GE January 2010  

Breast cancer (advanced or metastatic) - lapatinib: (2nd line) paper - post GE January 2010 ^{PDF 14 KB} 20 January 2010  

Evaluation report  

Appraising life - extending, end of life treatments paper  

Appraising life - extending, end of life treatments paper ^{PDF 23 KB} 21 October 2009  

Report by the Decision Support Unit  

Report by the Decision Support Unit ^{PDF 101 KB} 21 October 2009  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision ^{PDF 178 KB} 21 October 2009  

Non-manufacturer submissions  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support ^{PDF 17 KB} 21 October 2009  

Royal College of Nursing  

Royal College of Nursing ^{PDF 20 KB} 21 October 2009  

Royal College of Physicians  

Royal College of Physicians ^{PDF 35 KB} 21 October 2009  

Roche  

Roche ^{PDF 24 KB} 21 October 2009  

GlaxoSmithKline (including clarification required from NICE)  

Final submission  

Final submission ^{PDF 404 KB} 21 October 2009  

Responses to DSU questions  

Responses to DSU questions ^{PDF 161 KB} 21 October 2009  

Breast cancer (advanced or metastatic) - lapatinib: appeal information  

Breast cancer (advanced or metastatic) - lapatinib: appeal announcement information  

Appeals received  

Appeals received ^{PDF 115 KB} 08 June 2009  

Initial scrutiny letter  

Initial scrutiny letter ^{PDF 40 KB} 08 June 2009  

Response to scrutiny letter  

Response to scrutiny letter ^{PDF 73 KB} 08 June 2009  

Final scrutiny letter  

Final scrutiny letter ^{PDF 23 KB} 08 June 2009  

Clarification letter from appellant  

Clarification letter from appellant ^{PDF 23 KB} 08 June 2009  

Response to clarification letter  

Response to clarification letter ^{PDF 16 KB} 08 June 2009  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision  

Breast cancer (advanced or metastatic) - lapatinib: appeal decision ^{PDF 178 KB} 09 July 2009  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination information  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination  

Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination ^{PDF 167 KB} 05 March 2009  

Response to consultee, commentator and public comments on the ACD and comments from website consultation  

Response and comments to the website consultation on the Appraisal Consultation Document - prepared by the technical lead  

Response and comments to the website consultation on the Appraisal Consultation Document - prepared by the technical lead ^{PDF 170 KB} 05 March 2009  

Response to consultee and commentator comments on the Appraisal Consultation Document - prepared by the technical lead  

Response to consultee and commentator comments on the Appraisal Consultation Document - prepared by the technical lead ^{PDF 168 KB} 05 March 2009  

Consultee and commentator comments on the ACD  

Breakthrough Breast Cancer  

Breakthrough Breast Cancer ^{PDF 13 KB} 05 March 2009  

Department of Health  

Department of Health ^{PDF 12 KB} 05 March 2009  

GlaxoSmithKline - 1  

GlaxoSmithKline - 1 ^{PDF 70 KB} 05 March 2009  

GlaxoSmithKline - 2  

GlaxoSmithKline - 2 ^{PDF 205 KB} 05 March 2009  

National Collaborating Centre for Cancer  

National Collaborating Centre for Cancer ^{PDF 22 KB} 05 March 2009  

Royal College of Nursing  

Royal College of Nursing ^{PDF 19 KB} 05 March 2009  

Royal College of Physicians  

Royal College of Physicians ^{PDF 43 KB} 05 March 2009  

Roche  

Roche ^{PDF 110 KB} 05 March 2009  

Expert comments on the ACD  

Carolyn Rogers  

Carolyn Rogers ^{PDF 11 KB} 05 March 2009  

Justin Stebbing  

Justin Stebbing ^{PDF 12 KB} 05 March 2009  

Breast cancer (advanced or metastatic) - lapatinib: evaluation report  

Non-manufacturer submissions  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care, and Macmillian Cancer Support (joint submission)  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care, and Macmillian Cancer Support (joint submission) ^{PDF 29 KB} 09 October 2008  

Breast Cancer Care supporting letter  

Breast Cancer Care supporting letter ^{PDF 25 KB} 09 October 2008  

Department of Health (2)  

Department of Health (2) ^{PDF 21 KB} 09 October 2008  

National Collaborating Centre for Cancer  

National Collaborating Centre for Cancer ^{PDF 13 KB} 10 October 2008  

Roche  

Roche ^{PDF 37 KB} 10 October 2008  

Royal College of Nursing  

Royal College of Nursing ^{PDF 20 KB} 10 October 2008  

Royal College of Physicians  

Royal College of Physicians ^{PDF 46 KB} 10 October 2008  

Royal College of Pathologists  

Royal College of Pathologists ^{PDF 12 KB} 10 October 2008  

Sanofi Aventis  

Sanofi Aventis ^{PDF 26 KB} 10 October 2008  

Southampton Health Technology Assessment Centre  

Southampton Health Technology Assessment Centre ^{PDF 13 KB} 10 October 2008  

Manufacturer submission  

GlaxoSmithKline comments on ERG report  

GlaxoSmithKline comments on ERG report ^{PDF 245 KB} 10 October 2008  

GlaxoSmithKline response to ACD1  

GlaxoSmithKline response to ACD1 ^{PDF 107 KB} 10 October 2008  

GlaxoSmithKline appendices to ACD1  

GlaxoSmithKline appendices to ACD1 ^{PDF 779 KB} 10 October 2008  

GlaxoSmithKline addendum  

GlaxoSmithKline addendum ^{PDF 562 KB} 10 October 2008  

GlaxosmithKline response to clarification letter  

GlaxosmithKline response to clarification letter ^{PDF 217 KB} 10 October 2008  

NICE Clarification letter  

NICE Clarification letter ^{PDF 22 KB} 10 October 2008  

Decision Support Unit report  

DSU Report  

DSU Report ^{PDF 227 KB} 10 October 2008  

DSU specification form  

DSU specification form ^{PDF 67 KB} 10 October 2008  

DSU addendum to report  

DSU addendum to report ^{PDF 43 KB} 10 October 2008  

Rogers  

Rogers ^{PDF 27 KB} 10 October 2008  

Breast cancer (advanced or metastatic) - lapatinib: evaluation report  

Breast cancer (advanced or metastatic) - lapatinib: Evidence Review Group report  

Breast cancer (advanced or metastatic) - lapatinib: Evidence Review Group report ^{PDF 576 KB} 03 July 2008  

Breast cancer (advanced or metastatic) - lapatinib: Non-manufacturer submissions  

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care, and Cancerbackup (joint submission)  

Breast Cancer Campaign supporting letter  

Breast Cancer Campaign supporting letter ^{PDF 60 KB} 03 July 2008  

Breast Cancer Care supporting letter  

Breast Cancer Care supporting letter ^{PDF 23 KB} 03 July 2008  

Cancerbackup supporting letter  

Cancerbackup supporting letter ^{PDF 19 KB} 03 July 2008  

Breast cancer (advanced or metastatic) - lapatinib: Pre-meeting briefing  

Breast cancer (advanced or metastatic) - lapatinib: Pre-meeting briefing ^{PDF 162 KB} 03 July 2008  

British Association of Surgical Oncology  

British Association of Surgical Oncology ^{PDF 479 KB} 03 July 2008  

NCRI Breast Group, Joint Collegiate Council for Oncology, Royal College of Radiologists, Association of Clinical Pathologists and Royal College of Physicians (joint submission)  

NCRI Breast Group, Joint Collegiate Council for Oncology, Royal College of Radiologists, Association of Clinical Pathologists and Royal College of Physicians (joint submission) ^{PDF 38 KB} 03 July 2008  

Royal College of General Practitioners  

Royal College of General Practitioners ^{PDF 12 KB} 03 July 2008  

Royal College of Pathologists  

Royal College of Pathologists ^{PDF 11 KB} 03 July 2008  

GlaxoSmithKline  

GlaxoSmithKline ^{PDF 1018 KB} 01 July 2100  

Expert written personal statements  

Rogers  

Rogers ^{PDF 22 KB} 01 July 2100  

Sinnett  

Sinnett ^{PDF 22 KB} 01 July 2100  

Wilby  

Wilby ^{PDF 191 KB} 01 July 2100  

Update on status of lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer   

Update on status of lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer ^{PDF 13 KB} 26 March 2008  

Breast cancer (advanced or metastatic) - lapatinib: final scope  

Breast cancer (advanced or metastatic) - lapatinib: final scope ^{PDF 40 KB} 14 February 2007  

Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the scope  

Breast cancer (advanced or metastatic) - lapatinib: final scope ^{PDF 40 KB} 14 February 2007  

Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the matrix  

Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the matrix ^{PDF 21 KB} 14 February 2007  

Breast cancer (advanced or metastatic) - lapatinib: pre-referral scope  

Breast cancer (advanced or metastatic) - lapatinib: final scope ^{PDF 40 KB} 14 February 2007  

Breast cancer (advanced or metastatic) - lapatinib: pre-referral matrix  

Breast cancer (advanced or metastatic) - lapatinib: pre-referral matrix ^{PDF 42 KB} 14 February 2007